Arcadia Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcadia Biosciences, Inc. on July 1, 2026. The filing addresses two primary corporate governance matters: the disclosure of a discretionary cash bonus paid to the Chief Executive Officer for the 2025 fiscal year and the scheduling of the 2026 Annual Meeting of Stockholders.
Key Financial Metrics
The filing does not report company-wide revenue, profit, cash flow, or debt metrics. It focuses exclusively on executive compensation adjustments for the 2025 fiscal year:
- Thomas J. Schaefer (CEO/Interim CFO): Received a discretionary cash bonus of $169,000 for 2025 services. His total 2025 compensation was $473,058, comprising a $260,000 salary, the $169,000 bonus, $40,001 in option awards, and $4,057 in other compensation.
- Mark Kawakami (Former CFO): Received no bonus for 2025. His total 2025 compensation was $274,428, comprising a $212,063 salary, $40,001 in option awards, and $22,364 in other compensation.
- Other Officers: No other named executive officers received bonus payments for the 2025 year.
Material Changes and Commentary
Executive Compensation: The Board approved a discretionary bonus for Mr. Schaefer after previously noting in a Form 10-K/A that the amount was undeterminable. The filing clarifies that no bonuses were paid under the standard Executive Incentive Bonus Plan for 2025 due to the termination of a proposed business combination with Roosevelt Resources, LP in December 2025. Mr. Schaefer's bonus was discretionary rather than performance-based under the standard plan.
Annual Meeting: The 2026 Annual Meeting is scheduled for September 10, 2026. This date represents a change of more than 30 days from the anniversary of the 2025 meeting. Consequently, the deadline for stockholders to submit director nominations or proposals for inclusion in the proxy statement is July 13, 2026.
Outlook and Risks
The filing does not provide forward-looking financial guidance or discuss new material risks. It notes the historical context of the terminated business combination with Roosevelt Resources, LP as a factor in the 2025 compensation structure.
Key Facts for Investor Verification
- Verify the specific terms of the discretionary bonus paid to the CEO, as it deviated from the standard Executive Incentive Bonus Plan.
- Confirm the impact of the terminated Roosevelt Resources, LP transaction on the company's strategic direction and liquidity.
- Note the July 13, 2026 deadline for submitting stockholder proposals or director nominations for the September 10, 2026 Annual Meeting.
- Review the updated 2025 Summary Compensation Table to understand the shift from performance-based to discretionary compensation for the CEO.